TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34242246
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor inhibitors (TNFi) in combination with MTX
Study: 35856483
Drug: Dermapen and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermapen and topical coconut oil
Study: 35856483
Drug: Dermapen and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermapen and topical sesame oil
Study: 35856483
Drug: Periodontal mechanical
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periodontal mechanical treatment only
Study: 32122703
Drug: Photobiomodulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation treatment (GaAs diode laser, continuous wave 980nm, power 100mW, energy density 12J/cm2, applied on days 1, 3, 7, 14, 21, and 28 postoperatively)
Study: 33793678
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antiviral and nonsteroidal anti-inflammatory treatment
Study: 36083516
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) for 48 weeks
Study: 32040875
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment and Hall Technique (ART/HT)
Study: 35264075
Drug: Prebiotic-rich yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic-rich yogurt (100g daily for 6 weeks)
Study: 36450626
Drug: cobimetinib (cobi)
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: cobimetinib (cobi) 60 mg/day on days 1-21
Study: 36450626
Drug: cobimetinib (cobi)
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: cobimetinib (cobi) 40 mg/day on days 1-21 + venetoclax (ven) 800 mg/day on days 1-28
Study: 36450626
Drug: cobimetinib (cobi)
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: cobimetinib (cobi) 40 mg/day on days 1-21 + venetoclax (ven) 800 mg/day on days 1-28 + atezolizumab (atezo) 840 mg on days 1 and 15 of 28-day cycles
Study: 32586153
Drug: Invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive strategy with coronary angiography and optimal medical treatment
Study: 32586153
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy with only optimal medical treatment
Study: 32052831
Drug: Ceftriaxone 250
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days plus metronidazole for 14 days
Study: 32052831
Drug: Ceftriaxone 250
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days
Study: 34258686
Drug: Continuous antibiotic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antibiotic infusion (CAI) via an ambulatory pump
Study: 34258686
Drug: Standard pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pump and intermittent antibiotic administration (IAA)
Study: 33253659
Drug: Extensive intraoperative
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extensive intraoperative peritoneal lavage (EIPL) with 1 L of warm normal 0.9% saline, repeated ten times after surgery.
Study: 32303763
Drug: ALM 100
Normalized name: Atopalm 100 MG/ML Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALM 100 mg
Study: 32303763
Drug: ALM 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALM 200 mg
Study: 32303763
Drug: ZOL 10
Normalized name: danazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOL 10 mg
Study: 35742357
Drug: Tropocollagen gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropocollagen gel treatment (group A, n = 47)
Study: 34491449
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by dental students
Study: 34888663
Drug: Soluble corn
Normalized name: soluble corn fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble corn fiber (SCF) 20 g/day for 2 months
Study: 33328324
Drug: siponimod 2
Normalized name: siponimod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: siponimod 2 mg/d
Study: 39129649
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg daily
Study: 33922783
Drug: Caffeine loading
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine loading 40 mg/kg/day and maintenance 20 mg/kg/day
Study: 33922783
Drug: Caffeine loading
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine loading 20 mg/kg/day and maintenance 10 mg/kg/day
Study: 32985341
Drug: Topiramate 50
Normalized name: topiramate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 50 to 100 mg/day
Study: 36205549
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (RW) consumption (250 mL/d, 5 d/wk for 3 weeks)
Study: 32340155
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive training intervention with lab-based tasks, specific dosage and duration not mentioned.
Study: 34899426
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy (DBT‐bt)
Study: 35954975
Drug: General psychoeducation
Approvals — FDA: no, EMA: no, PMDA: no
Description: General psychoeducation about psychological treatments for mental health
Study: 36036731
Drug: ADD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADD group (n=15) consuming pecans (68 g) as part of a free-living diet
Study: 36036731
Drug: SUB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUB group (n=16) substituting pecans (68 g) for isocaloric foods from their habitual diet
Study: 35667721
Drug: Immediate initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate initiation of anti-TB therapy
Study: 35667721
Drug: Sepsis-specific dose
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sepsis-specific dose anti-TB therapy
Study: 33588893
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (1 g of ferric carboxymaltose) when hepcidin < 20 μg/l and intravenous iron and erythropoietin for 20 ≤ hepcidin < 41 μg/l.
Study: 33588893
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron treatment according to hepcidin levels.
Study: 33891907
Drug: Full-dose anticoagulation
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose anticoagulation with rivaroxaban 20 mg once daily (or full-dose heparin if oral administration is not feasible) for 30 days
Study: 33891907
Drug: Full-dose anticoagulation
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban through 30 days
Study: 33891907
Drug: Full-dose anticoagulation
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose anticoagulation with rivaroxaban or enoxaparin
Study: 33141770
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotic therapy
Study: 32345383
Drug: New equation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New equation for estimating 24-h urinary Na excretion from casual spot urine specimen
Study: 35022159
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of BNT162b2 vaccine
Study: 37609358
Drug: High-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose subcutaneous treprostinil
Study: 37609358
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous treprostinil
Study: 33200489
Drug: Fosmetpantotenate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmetpantotenate (300 mg oral dose three times daily)
Study: 32887379
Drug: Capsinoid (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoid (9 mg/day) for 6 weeks
Study: 32887379
Drug: Capsinoid (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoid (9 mg/day) for 6 weeks in overweight subgroup
Study: 32887379
Drug: Capsinoid (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoid (9 mg/day)
Study: 35751657
Drug: Midostaurin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin with concomitant strong CYP3A4 inhibitors
Study: 32389735
Drug: Gabapentin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (single dose preoperatively)
Study: 32389735
Drug: Control (acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (acetaminophen and celecoxib alone)
Study: 32772826
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg or 10 mg of melatonin
Study: 33389304
Drug: Secret Agent
Normalized name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 6 g in 100 g / PADIMATE O 8 g in 100 g TOPICAL LIPSTICK [Phineas and Ferb Sun Smacker SPF 24 Secret Agent Strawberry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secret Agent Society (SAS)
Study: 32020185
Drug: TLR3 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR3 and TNF treatment of human IECs.
Study: 35060609
Drug: UMC+CC (Usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMC+CC (Usual Medical Care plus Chiropractic Care)
Study: 35060609
Drug: UMC+CC
Normalized name: XCEL-UMC-BETA
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMC+CC
Study: 36048042
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 16 weeks
Study: 33310502
Drug: Pharmacotherapy (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (monotherapy with selective serotonin reuptake inhibitors, SSRI, or selective serotonin noradrenalin reuptake inhibitors, SSNRI)
Study: 32899492
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine intervention (250 mL of wine/day, 4 weeks)
Study: 35317615
Drug: Ticagrelor +
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor + Aspirin
Study: 37580610
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 32706122
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin A (BoNT‐A) injections
Study: 32960827
Drug: Oral glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glutathione (reduced glutathione) daily for 24 weeks
Study: 33846983
Drug: Lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine cream
Study: 35675902
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no morphine)
Study: 35186959
Drug: α-Lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-Lipoic acid (ALA) 1200 mg/d, intravenous infusion once daily plus standard care
Study: 35186959
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus equal volume saline infusion (placebo)
Study: 35107113
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g day-1 of GP seasoning
Study: 35179770
Drug: Persian barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persian barley water (PBW) 250 ml daily for two weeks
Study: 34334656
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (chemo ± radiation)
Study: 32966959
Drug: Interpersonal Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal Therapy (IPT)
Study: 39235772
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 8 weeks
Study: 34464524
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy for Preventing Suicide Behavior (MBCT-S)
Study: 34464524
Drug: Enhanced treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment-as-usual (eTAU)
Study: 32354590
Drug: Anesthetic cream
Normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic cream
Study: 34430347
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2) + pemetrexed (500 mg/m2) + bevacizumab (15 mg/kg) (CisPemBev)
Study: 34430347
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 6 mg/mL/min) + paclitaxel (200 mg/m2) + bevacizumab (15 mg/kg) (CarPacBev)
Study: 35975917
Drug: OUD pharmacotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OUD pharmacotherapy
Study: 35975917
Drug: Study medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication
Study: 35975917
Drug: Study medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication duration
Study: 35975917
Drug: Baseline sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline sedative use
Study: 33964907
Drug: Single 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 6 ml Hylan G-F 20 injection
Study: 32326980
Drug: Smartphone-based digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based digital cognitive behavioural therapy (CBT) intervention
Study: 34560012
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (10 mg orally twice daily for 12 weeks) plus high-dose dexamethasone (40 mg/day intravenously for 4 consecutive days)
Study: 34560012
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone alone (40 mg/day intravenously for 4 consecutive days)
Study: 35713247
Drug: PDRN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDRN treatment (two consecutive injections of PDRN one and two days after surgery)
Study: 35713247
Drug: PDRN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDRN treatment
Study: 34807494
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.5 mg/kg bolus followed by 0.25 mg·kg−1·h−1 infusion)
Study: 34807494
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (equivalent dose and regimen to ketamine)
Study: 33487035
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D supplementation
Study: 32273054
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonists (MRAs)
Study: 32676136
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (PMTA, PCEM, RCT)
Study: 36295619
Drug: Laser micro-grooved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser micro-grooved (LMG) platform switched implants and abutments (I&A)
Study: 33500235
Drug: Shockwave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shockwave therapy
Study: 34403648
Drug: MgSO4 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 (60 mg.kg‐1) with rocuronium 0.3 mg.kg‐1
Study: 34403648
Drug: MgSO4 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 (60 mg.kg‐1) with rocuronium 0.6 mg.kg‐1
Study: 34403648
Drug: MgSO4 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 (60 mg.kg‐1) with rocuronium 1.2 mg.kg‐1
Study: 34403648
Drug: Control (saline)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (saline) with rocuronium 0.3 mg.kg‐1
Study: 34403648
Drug: Control (saline)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (saline) with rocuronium 0.6 mg.kg‐1
Study: 34403648
Drug: Control (saline)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (saline) with rocuronium 1.2 mg.kg‐1
Study: 32981192
Drug: Days with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days with clinical hypoglycemia (54-69 mg/dL)
Study: 32981192
Drug: Days with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days with clinically serious hypoglycemia (<54 mg/dL)
Study: 35710444
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (STI screening and treatment and risk-reduction counseling without dPEP)
Study: 33275326
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone and bupropion (NB)
Study: 35911215
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality serious game training program, twice a day for at least 10 days during hospitalization
Study: 33838565
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of 1 tablet containing 10 mg enalapril and 0.8 mg folic acid
Study: 33838565
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of 1 tablet containing 10 mg enalapril only
Study: 37872497
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg)
Study: 35967104
Drug: Atacicept 75
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept 75 mg
Study: 34185386
Drug: Neural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural therapy (NT)
Study: 35875898
Drug: Osteopathic Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Medicine (OM)
Study: 34006898
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NCT) with adriamycin and cyclophosphamide followed by docetaxel
Study: 34006898
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy (NET) with goserelin and tamoxifen
Study: 32460241
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract (600 mg/day for 7 days)
Study: 32059692
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg PO bid
Study: 32059692
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg PO bid plus dapagliflozin 10 mg PO qd
Study: 33835174
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg orally 60 minutes before chemotherapy on day 1 and 80 mg orally each morning of days 2 and 3; palonosetron, 0.25 mg intravenously; dexamethasone, 6 mg orally 30 minutes before chemotherapy initiation on day 1)
Study: 33835174
Drug: Placebo (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (125 mg orally 60 minutes before chemotherapy on day 1 and 80 mg orally each morning of days 2 and 3; palonosetron, 0.25 mg intravenously; dexamethasone, 12 mg orally 30 minutes before chemotherapy initiation on day 1)
Study: 34476568
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 mg twice a day for 4 weeks)
Study: 36052527
Drug: 60 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 days of head-down bed rest (HDBR) with daily multivitamin supplementation
Study: 32039461
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment (radiation therapy) for early endometrial cancer
Study: 34016037
Drug: Anabolic steroid
Normalized name: Anabolic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic steroid (Nandrolone Decanoate)
Study: 33425079
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) + treatment as usual (TAU)
Study: 36522805
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d pure EPA (ethyl ester, ≥97% purity) for 10 weeks
Study: 36522805
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d pure DHA (ethyl ester, ≥97% purity) for 10 weeks
Study: 35030335
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus chemotherapy (360 mg nivolumab intravenously every 3 weeks plus oxaliplatin-based chemotherapy)
Study: 35030335
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (placebo plus oxaliplatin-based chemotherapy)
Study: 38906161
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus chemotherapy
Study: 35921605
Drug: LEN (Lenvatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEN (Lenvatinib monotherapy)
Study: 34120160
Drug: S-methyl-L-thiocitrulline (SMTC)
Normalized name: methyl lactate, L-
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-methyl-L-thiocitrulline (SMTC)
Study: 35445439
Drug: 5-HT2 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5-HT2 antagonist cyproheptadine
Study: 37330257
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy for Seasonal Affective Disorder (CBT-SAD)